These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 29126203)
1. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Chinnaiyan P; Won M; Wen PY; Rojiani AM; Werner-Wasik M; Shih HA; Ashby LS; Michael Yu HH; Stieber VW; Malone SC; Fiveash JB; Mohile NA; Ahluwalia MS; Wendland MM; Stella PJ; Kee AY; Mehta MP Neuro Oncol; 2018 Apr; 20(5):666-673. PubMed ID: 29126203 [TBL] [Abstract][Full Text] [Related]
2. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Galanis E; Anderson SK; Miller CR; Sarkaria JN; Jaeckle K; Buckner JC; Ligon KL; Ballman KV; Moore DF; Nebozhyn M; Loboda A; Schiff D; Ahluwalia MS; Lee EQ; Gerstner ER; Lesser GJ; Prados M; Grossman SA; Cerhan J; Giannini C; Wen PY; Neuro Oncol; 2018 Mar; 20(4):546-556. PubMed ID: 29016887 [TBL] [Abstract][Full Text] [Related]
4. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Chinnaiyan P; Won M; Wen PY; Rojiani AM; Wendland M; Dipetrillo TA; Corn BW; Mehta MP Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):880-4. PubMed ID: 23725999 [TBL] [Abstract][Full Text] [Related]
5. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562 [TBL] [Abstract][Full Text] [Related]
6. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Butowski N; Chang SM; Lamborn KR; Polley MY; Pieper R; Costello JF; Vandenberg S; Parvataneni R; Nicole A; Sneed PK; Clarke J; Hsieh E; Costa BM; Reis RM; Hristova-Kazmierski M; Nicol SJ; Thornton DE; Prados MD Neuro Oncol; 2011 Dec; 13(12):1331-8. PubMed ID: 21896554 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Ma DJ; Galanis E; Anderson SK; Schiff D; Kaufmann TJ; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Flynn PJ; Ligon KL; Buckner JC; Sarkaria JN Neuro Oncol; 2015 Sep; 17(9):1261-9. PubMed ID: 25526733 [TBL] [Abstract][Full Text] [Related]
11. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646 [TBL] [Abstract][Full Text] [Related]
12. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943 [TBL] [Abstract][Full Text] [Related]
13. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244. Elinzano H; Glantz M; Mrugala M; Kesari S; Piccioni DE; Kim L; Pan E; Yunus S; Coyle T; Timothy K; Evans D; Mantripragada K; Boxerman J; DiPetrillo T; Donahue JE; Hebda N; Mitchell KM; Rosati KL; Safran H Am J Clin Oncol; 2018 Feb; 41(2):159-162. PubMed ID: 26658237 [TBL] [Abstract][Full Text] [Related]
15. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161 [TBL] [Abstract][Full Text] [Related]
16. High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma. Achari R; Arunsingh M; Badgami RK; Saha A; Chatterjee S; Shrimali RK; Mallick I; Arun B Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):335-343. PubMed ID: 28188088 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813 [TBL] [Abstract][Full Text] [Related]
18. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354 [TBL] [Abstract][Full Text] [Related]
19. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]